Press Detail





Biotest AG: Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics

Biotest AG / Miscellaneous



Corporate news transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Biotest Diagnostics Corporation Announces Appointment of Vice President,
Transfusion Diagnostics

Denville, NJ / Dreieich, 20 October 2006. Biotest Diagnostics Corporation
(BDC), a subsidiary of Biotest AG, a worldwide supplier of manual and
automated solutions to the blood bank industry, announces the appointment
of Candace K. Williams to the newly created position of Vice President of
Transfusion Diagnostics. Ms. William’s responsibilities will focus on
helping BDC strategically position and expand the manual and automated
blood group serology business in North America.

Most recently, Ms. Williams has been serving as the Director of
Immunohematology Systems for Olympus America. While at Olympus, she was
responsible for their automated blood bank systems achieving over a 90%
market share in donor centers and was responsible for the TANGO® Automated
Blood Bank System.  Before joining Olympus, she worked at Parkland Memorial
Hospital and University of Texas Health Science Center in Dallas, TX where
she obtained her Specialty in Blood Bank certification. She has been active
in the American Association of Blood Banks, currently serving as the Chair
of the Exhibitor Advisory Committee and as a member of the Educational
Advisory Committee.

In her new position at Biotest, Ms. Williams will be responsible for sales,
marketing and support of the Biotest Manual Blood Group Serology Reagents
and the TANGO Automated Blood Bank System in U.S. hospitals.  The manual
blood bank reagents are currently available in Canada and under review by
the Food and Drug Administration in the United States. The TANGO System is
available in all of North America.

“We are focused on the expansion of our blood banking business with the
manual and automated blood bank product lines in North America,” said Bill
Weiss, President, Biotest Diagnostics Corporation. “Ms. Williams’s
extensive blood bank experience and success with automated blood bank
systems will enable her to lead Biotest forward in the area of transfusion
diagnostics.”

“I am excited to join Biotest because of their aggressive plans to become a
leader in the North American blood bank market,” said Williams. “In recent
years I have had the opportunity to work with Biotest’s outstanding
automated and manual blood group serology product lines. While our efforts
will initially focus on the TANGO Automated Blood Bank System for the
hospital market, our strategic plans call for expanding the automated and
manual offerings in the very near future.”


About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulines, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In addition, Biotest also researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and blood cancer. The Diagnostic segment spans
reagents and serology and microbiology systems which are used, for example,
in blood transfusions. Biotest has around 1,100 employees worldwide and its
shares are listed in the Frankfurt Stock Exchange's Prime Standard.

Biotest AG: Dr. Michael Ramroth, Telefon: +49 (0) 6103 801-338 
Telefax: +49 (0) 6103 801-347, E-Mail: michael.ramroth@biotest.de
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de

German Securities Code Number, ISIN ordinary shares: 522720, DE0005227201
German Securities Code Number, ISIN preferred shares: 522723, DE0005227235
Listed: Prime Standard/Official market
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart





DGAP 20.10.2006 
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
WWW:          www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      
Listed:       Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
              Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------